

Index

Note: page numbers in *italics* refer to figures and **bold** refer to tables.

- 4 Ts scoring system, 55, **55**
- ACE inhibitors, 112, 182, 208
- acid–base metabolism, 91–92
- activated clotting time (ACT), 53, 58
- acute kidney injury (AKI), 203
 - definitions, 203–204
 - etiology, 206–207
 - endotoxins, 207
 - hypoxia, 207
 - systemic inflammatory response syndrome, 207
- laboratory evaluation, **205**
- outcomes, **204**, 204
- prevention, 207–209
- risk factors, 205–206
- therapy, 209–211
 - hyperkalemia, 209–210
 - hyponatremia, 210
 - hyponatremia, 210
 - oliguria, 210
 - renal replacement therapy, 210–211
- acute respiratory failure, 244–245
 - pulmonary embolism, 244–245
- adrenaline (epinephrine), 126–127
- air embolism, 68
- air in the heart, 121, 122
- alarms, 20, 40–41
 - settings adjustment for weaning, 120
- albumin priming solution, 46
- anemia, hemodilutional, 174–175
- anesthesia, 119
 - deep hypothermic circulatory arrest, 154–155
 - pediatric patients, 230
- anesthetic preconditioning, 112
- angiotensin receptor antagonists, 112, 208
- antegrade cerebral perfusion (ACP), 91, 160–161
 - intermittent ACP, 160
 - pediatric patients, 234
 - techniques, 161
 - versus retrograde cerebral perfusion, 161
- anti-arrhythmic drugs, 120
- antibiotic prophylaxis, 230
- anticoagulation, 51, 75
 - direct thrombin inhibitors, 56–57
 - extracorporeal membrane oxygenation, 222
- heparin, 52–55
 - low-molecular-weight heparin, 56
- monitoring, 58–60
 - platelet function tests, 59–60, **61**
 - point-of-care tests, 58, 60
- pediatric patients, 234
- preparation for weaning from CPB, 118
- reversal, 57–58, 124–125
- VAD patients, 149
- anti-diuretic hormone (ADH), 128
- antifibrinolytic agents, 62
- antiplatelet agents, 181
- aortic aneurysms, 249–250
 - reducing spinal cord ischemia during surgery, 250
- aortic cross-clamping, 110, 111
 - clamp removal, 119
 - intermittent, 108
 - stroke relationships, 192–193
- aortic dissection, 248–249
- aortic injury, 241, 250–251
- argatroban, 56
- arterial cannulae, 5–6, 6, 67–68
 - flow rates, 5
 - performance index, 67
- arterial cannulation, 67–70
 - aortic root cannulation
 - complications, 68–69, **69**
 - connection to the patient, 68
 - pediatric patients, 233
 - peripheral, 69–70
 - complications, **70**
 - indications, 69
- arteriovenous malformations, 245
- aspirin, 112, 181
 - stroke risk relationship, 194, 195
- atrial fibrillation, 194
- autologous blood priming, 43, 88–89
- beta blockers, 112
- bicarbonate buffer system, 91
- bipyridine phosphodiesterase-III (PDE III) inhibitors, 127
- bivalirudin, 57
- bleeding
 - causes, 63
 - extracorporeal membrane oxygenation complication, 225
 - gastrointestinal, 178
 - management, 63–64, 118
 - cardiotomy suction, 73
 - transfusion, 64
 - VAD patients, 149
 - prevention, 62
 - antifibrinolytic agents, 62
 - heparin dosing, 62
 - protamine dosing, 62
- blood
 - as priming solution, 44
 - autologous blood priming, 43
 - problems with, **44**
- blood cardioplegia, 105
- blood gas analysis
 - pediatric patients, 235
- blood gas management, 92–93
 - analysis prior to weaning, 121
 - deep hypothermic circulatory arrest, 159–160
 - monitoring, 96
 - pediatric patients, 235
- bowel ischemia, 179

- bradykinin, 172
 brain injury, 186
 brain tumors, 246
 brainstem auditory evoked potentials (BAEPs), 164
 Bretschneider's solution, 105
- calcium
 accumulation in myocytes, 106
 failure to wean management, 128
 ischemia-reperfusion injury pathology, 173
 levels, 94, 117
 cannulae. *See* arterial cannulae
 cannulation. *See* arterial cannulation
 cardiac arrest
 induction, 102–105
 traumatic, 241
 cardiac surgery complications, 177
 cardiac trauma, 241
 cardiogenic shock, 139
 causes, 139
 CARDIOHELP system, 242
 cardioplegia, 102
 components of, 102–106
 additives to solutions, 106
 chemical cardiac arrest induction, 102–105
 solution composition, 104, 234
 delivery systems, 16, 17, 18, 18, 107, 107–108
 antegrade delivery, 107
 retrograde delivery, 107–108
 cardiopulmonary bypass
 (CPB), 67, *See also* non-cardiac surgical functions of CPB
 central venous pressure, 78
 children. *See* pediatric patients
 circuit set-up, 2, 24–26, 34–40, *See also* priming
 mini-bypass system, 27
 pediatric patients, 231–234
 pre-bypass checklist, 28, 29
 electrocardiogram, 79
 flow rate. *See* flow rates
 general perioperative management, 112–113
 hemodilution, 77–78
 left atrial pressure, 78
 mean arterial blood pressure, 78
 metabolism during. *See* metabolic management
 off-pump coronary artery bypass graft surgery (OPCABG), 182–183
 protocol, 82–85
 pulmonary pressure, 78
 re-warming, 84–85
 temperature, 79
 termination. *See* weaning from CPB
 transesophageal echocardiography, 80
 transitioning the patient onto, 82–83
 connecting the circuit, 82–83
 initiating bypass, 83
 urine volume, 79
 cardiopulmonary bypass machine, 1, *See also* mini-bypass system
 alarms, 20, 40–41
 arterial cannulae, 5–6
 cardioplegia delivery systems, 16
 components, 4
 filters, 13–15
 gas supply system, 13
 hemofilters, 17
 mini-bypass system, 20
 monitoring, 4, 18–20
 oxygenators, 11–13
 preparation, 24–26, 34–40
 See also priming
 pump heads, 7–9
 reservoirs, 9–11
 suckers and vents, 15–16
 tubing, 2–4
 venous cannulae, 6–7
 cardiotomy suction, 73
 adverse effects, 73
 reduction strategies, 73
 pediatric patients, 233
 catecholamines, 112
 cefuroxime, 230
 central venous pressure (CVP), 78
 centrifugal pumps, 9, 10, 220
 cerebral blood flow (CBF)
 antegrade cerebral perfusion (ACP), 160–161
 pediatric patients, 234
 autoregulation, 159
 determinants, 186–188, 188, 189, 189
 retrograde cerebral perfusion (RCP), 160
 cerebral ischemia, 188–190, *See also* stroke
 neurocognitive outcome relationship, 199, 199
 perfusion pressure effect, 189
 cerebral physiology during CPB, 186–188
 cerebrospinal fluid drainage, 162
 chest splinting, 129
 children. *See* pediatric patients
 Chitwood clamp, 110, 111
 cholecystitis, 179
 chronic kidney disease (CKD)
 dialysis-dependent patient management, 209
 non-dialysis-dependent patient management, 209
 clopidogrel, 181
 coagulation cascade, 51–52, 52
 coagulation disorders after CPB, 60–62
 fibrinolysis, 62
 heparin rebound, 61
 hypothermia effects, 62
 platelet abnormalities, 60–61
 systemic inflammatory response syndrome (SIRS), 61
 cognitive outcomes. *See* neurocognitive outcomes
 colloid priming solutions, 45–46
 albumin, 46
 dextrans, 46
 gelatins, 46
 hydroxyethyl starch (HES), 46
 problems with, 47
 complement activation, 170, 171
 continuous veno-venous hemofiltration (CVVH), 146
 corticosteroids, 162
 pediatric patients, 230
 prophylaxis, 181
 cross-circulation technique, 1, 3
 crystalloid solutions, 44–45, 105

- crystalloid solutions (cont.)
 - balanced crystalloid solutions, 45
 - dextrose, 44–45
 - problems with, 45
 - Custodiol solution, 105
 - cytokines, 172
 - de-airing the heart, 121
 - deep accidental hypothermia, 239
 - deep hypothermic circulatory arrest (DHCA), 91, 152
 - anesthesia, 154–155
 - applications, 153
 - circulatory arrest, 156
 - cooling, 156
 - extracorporeal circulation, 155
 - hemostasis, 158
 - historical roots, 152–153
 - neurological monitoring, 163–164
 - neuroprotection, 158–162
 - acid–base management, 159–160
 - antegrade cerebral perfusion (ACP), 160–161
 - glycemic control, 162
 - hemodilution, 159
 - hypothermia, 158–159, 159
 - leukocyte depletion, 161–162
 - pharmacological protection, 162
 - retrograde cerebral perfusion (RCP), 160
 - spinal cord protection, 162
 - outcome, 165
 - neurological, 165
 - non-neurological, 165
 - postoperative care, 165
 - re-warming, 157
 - safe duration, 157, 157
 - surgical considerations, 156
 - tumor resection, 245
- desmopressin, 63
 - dextran priming solutions, 46
 - dextrose priming solution, 44–45
 - dialysis
 - management of dialysis-dependent patients, 209
 - prophylactic, 208
 - direct current cardioversion, 120
 - direct thrombin inhibitors (DTIs), 56–57
 - argatroban, 56
 - bivalirudin, 57
 - disseminated intravascular coagulation (DIC), 61
 - diuretics
 - acute kidney injury prevention, 207
 - oliguria management, 210
 - dobutamine, 127
 - dopamine, 127, 208
 - drug dilution and loss, 95–96
 - electric failure alarms, 41
 - electrocardiogram (ECG), 79
 - electroencephalography (EEG), 164
 - electrolytes, 93–94
 - analysis prior to weaning, 121
 - monitoring, 96
 - preparation for weaning from CPB, 117–118
 - electronic safety devices, 40–41
 - emboli, 68, 174
 - emergency cardiopulmonary support (ECPS), 241–244
 - indications, 242
 - portable devices, 241, 242
 - endoclamp, 110, 111
 - endothelial activation, 170
 - endotoxins, 174
 - acute kidney injury etiology, 207
 - enoximone, 127
 - enzyme-linked immunosorbent assay (ELISA), 54
 - epiaortic scanning, 191
 - epicardial pacing, 121–122
 - epinephrine, 126–127
 - epsilon-aminocaproic acid (EACA), 62, 63
 - evoked potential monitoring, 164
 - Extracorporeal Life Support Organization (ELSO), 215
 - extracorporeal membrane oxygenation (ECMO), 214, 215, 243
 - circuit components, 219–221
 - membrane oxygenator, 220, 221, 222
 - pumps, 219–220
 - complications, 224–226
 - circuit-related, 225–226
 - patient-related, 225
 - configuration, 216–219, 217
 - VA-ECMO, 130, 218–219
 - VV-ECMO, 217–218, 218
 - future trends, 226
 - history, 214–215
 - indications and contraindications, 215–216, 216, 243
 - maintenance, 222–224, 223
 - nomenclature, 215
 - pediatric patients, 236–237
 - safety, 222
 - set-up, 243–244
 - weaning, 224
- fenoldapam, 208
 - fibrillation induction, 108
 - fibrin, 172
 - fibrinogen concentrates, 63
 - fibrinolysis, 62
 - fibrinolytic system activation, 172
 - filters, 13–15, 14, 15
 - flow rates, 76–77, 77, 83–84, 89–91
 - hypoperfusion, 89–90
 - pediatric patients, 233–234
 - temperature and hypothermia management, 90
 - fluid balance, pediatric patients, 234
 - fluid replacement, 118
 - furosemide, 208
 - gas alarms, 40
 - gas supply system, 13, 14
 - gastrointestinal complications, 176–179, 177
 - bleeding, 178
 - bowel ischemia, 179
 - hepatic complications, 179
 - pancreatitis, 179
 - pathogenesis, 176–178
 - risk factors, 178
 - gelofusine priming solution, 46
 - glucose management, 94–95, 117
 - neurological outcome and, 190
 - neuroprotection, 162
 - pediatric patients, 235

- glycemic control. *See* glucose management
 glyceryl trinitrate (GTN), 128
 gravity siphoning, 70
- heart failure, 139
 causes, **139**
 HeartMate II, 142–144, *144*,
 HEARTSTRING system, 193
 HeartWare HVAD, 144–145,
 145, *146*
 hemodilution, 42–43, 77–78, **88**
 drug dilution and loss, 95–96
 metabolic effects, 87–88
 neuroprotection, 159
 hemodilutional anemia,
 174–175
 hemodynamic calculations, **89**
 hemofilters, 17, *19*
 hemofiltration, 95, 182
 continuous veno-venous
 hemofiltration
 (CVVH), 146
 pediatric patients, 234
 hemostasis. *See* anticoagulation
 heparin, 52–55, 75
 anticoagulation mechanism,
 52–53
 dosing, 53, 62
 low-molecular-weight
 heparin (LMWH), 56
 monitoring, 53
 neutralization, 57–58
 heparinase, 58
 methylene blue, 58
 platelet factor 4 (PF4), 57
 protamine, 57, 124–125
 rebound, 61
 resistance, 53
 structure, 52
 heparinase, 58
 heparin-bonded circuitry, 182
 heparin-induced platelet
 activation assay
 (HIPA), 54,
 heparin-induced
 thrombocytopenia
 (HIT), 53–55
 management, 55
 hepatic complications, 179
 histidine-tryptophan-
 ketoglutarate (HTK),
 105
 hydroxyethyl starch priming
 solution, 46
 hypercalcemia, 105
 hyperglycemia, 94–95, 117
 pediatric patients, 235
 hyperkalemia, 93, 117
 hypothermia diagnosis, 239
 kidney injury relationship,
 209–210
 therapy, 209–210
 hyponatremia management,
 210
 hyperthermia, 157, 165, 190
 hypofibrinogenemia, 63
 hypoglycemia, neonates, 235
 hypokalemia, 93, 117
 hyponatremia management,
 210
 hypoperfusion, 89–90
 hypotension, 126
 hypothermia, 62, 63, 153, *See*
 also deep hypothermic
 circulatory arrest
 (DHCA)
 classification, **90**
 complications, 175
 flow rate relationship, 90
 hypothermic CPB, 79, **80**
 re-warming, 84–85
 myocardial, 102, 105–106
 pathophysiology, 153, **154**
 re-warming, 116–117
 severe hypothermia,
 239–240
 stages of, **240**
 hypoxanthine accumulation,
 173–174
- infection, with extracorporeal
 membrane
 oxygenation, 225
 in-line blood gas analysis,
 18–19, *19*
 inotropic support, 123
 failure to wean, 126–129
 insulin infusions, 94
 Interagency Registry of
 Mechanically Assisted
 Circulatory Support
 (INTERMACS), 137
 intra-aortic balloon pump
 (IABP), 119, 126, 129,
 132–135
 beneficial effects of, **133**
 combined with continuous
 veno-venous
 hemofiltration, 146
 complications, 135
 indications for, **133**
 patient management,
 134–135
 ischemia, 173
 ischemia-reperfusion injury,
 173–174
 altered calcium handling,
 173
 hypoxanthine accumulation,
 173–174
 oxygen free radical
 production, 173
 ischemic preconditioning, 109
- jugular venous oxygen
 saturation monitoring,
 163
- kallikrein, 171, 172
 kidney disease. *See* acute kidney
 injury (AKI)
 kinin system activation, 171
- laboratory investigations, 80
 lactate, 118
 management, 95
 latex rubber, 3
 left atrial pressure, 78
 left ventricular assist device
 (LVAD), 136, 148–149
 leukocyte depletion, 161–162,
 182
 leukocytes, 172
 levosimendan, 128
 liver transplantation, 247
 low cardiac output syndrome,
 126
 low-molecular-weight heparin
 (LMWH), 56
 lung transplantation, 246–247
- magnesium, 94, 106, 117, 121
 mannitol, 46–47, 106, 208
 mean arterial blood pressure
 (MAP), 78
 cerebral blood flow
 relationship, 187, *188*
 mechanical circulatory
 support, 132
 intra-aortic balloon pump
 (IABP), 132–135
 types of, **133**
 ventricular assist devices
 (VADs), 136–150
 mechanical ventilation, 120
 metabolic acidosis, 92, 118
 management, 121, 209–210

Cambridge University Press

978-1-107-42825-6 - Cardiopulmonary Bypass: Second Edition

Edited by Sunit Ghosh, Florian Falter and Albert C. Perrino

Index

[More information](#)

- metabolic alkalosis, 92
- metabolic management, 87
 - acid–base metabolism, 91–92
 - blood gas management, 92–93
 - CPB effects on metabolism, 87–89
 - circuit primes, 87–88
 - CPB circuit primes, 88–89
 - electrolytes, 93–94
 - flow rates and, 89–91
 - glucose, 94–95
 - hemofiltration, 95
 - lactate, 95
 - monitoring, 96
- methylene blue, 58
- milrinone, 127
- mini-bypass system, 20, 21, 81–82
 - circuit assembly, 27
 - priming, 28, 42
 - safety features, 26–27
- minimal access cardiac surgery, 110–112
- modified ultrafiltration (MUF), 236
- monitoring, 18–20
 - anticoagulation status, 58–60
 - heparin monitoring, 53
 - platelet function tests, 59–60, 61
 - point-of-care tests, 58, 60
 - in-line blood gas analysis, 18–19, 19
 - metabolic and physiological parameters, 96
 - neurological monitoring, 163–164
 - oxygen saturation, 19–20, 20
 - mixed venous oxygen saturation, 96
 - pediatric patients, 230–231, 234–235
- motor evoked potential (MEP) monitoring, 164
- myocardial damage during CPB, 100, 101, 180–181, *See also* cardioplegia
- perioperative myocardial infarction, 101
- protection, 100–101
 - general perioperative management, 112–113
 - goals and principles, 101–102
- intermittent ischemia and reperfusion, 108
- ischemic preconditioning, 109
- myocardial hypothermia, 102, 105–106
- myocardial oxygen demand, 102
- off-pump coronary bypass graft surgery (OPCABG), 108–109
- pharmacologic preconditioning, 110
- N*-acetylcysteine, 208
- natriuretic peptides, 208
- near infra-red spectroscopy (NIRS), 163, 164
 - pediatric patients, 230
- neurocognitive outcomes, 197–199
 - cerebral ischemia relationship, 199, 199
 - deep hypothermic circulatory arrest, 165
- neurological complications, 186, *See also* stroke
- extracorporeal membrane oxygenation, 225
- glucose control effect, 190
- perfusion pressure effect, 189
- temperature effect, 190
- neurological monitoring, 163–164
 - neurological function, 164
 - substrate delivery, 163–164
- neuroprotection
 - acid–base management, 159–160
 - antegrade cerebral perfusion (ACP), 160–161
 - glycemic control, 162
 - hemodilution, 159
 - hypothermia, 158–159, 159
 - deep hypothermic circulatory arrest, 158
 - leukocyte depletion, 161–162
 - pharmacological protection, 162
 - retrograde cerebral perfusion (RCP), 160
 - spinal cord protection, 162
- neutrophil activation, 172
- neutrophil gelatinase-associated lipocalin (NGAL), 204
- newborns, 229, 235, *See also* pediatric patients
- nitric oxide, 128–129
- non-bicarbonate buffers, 91
- non-cardiac surgical functions of CPB
 - acute respiratory failure, 244–245
 - emergency cardio-pulmonary support, 241–244
 - non-cardiac transplantation, 246–247
 - re-warming from severe hypothermia, 239–240
 - thoracic aortic surgery, 248–251
 - trauma care, 240–241
 - tumor resection, 245
- non-pulsatile flow, 174
- noradrenaline (norepinephrine), 127–128
- off-pump coronary bypass graft surgery (OPCABG), 108–109
 - neurocognitive outcome and, 198, 198
 - stroke incidence and, 191–192, 192
 - versus CPB, 182–183
- oliguria management, 210
- organ damage
 - pathophysiology, 168
 - blood–surface interface, 168–169
 - embolism, 174
 - endotoxins, 174
 - hemodilutional anemia, 174–175
 - ischemia-reperfusion injury, 173–174
 - non-pulsatile flow, 174
 - organ perfusion alterations, 175, 176
 - systemic inflammatory response syndrome, 169–173
 - temperature, 175
 - therapeutic strategies, 181–182
- oxygen consumption, 76, 89
 - calculations, 89
- oxygen free radical production, 173

- oxygen saturation
 jugular venous oxygen
 saturation monitoring, 163
 monitoring, 19–20, 20
 mixed venous oxygen
 saturation, 96
 oxygenators, 11–13, 12, 13
 extracorporeal membrane
 oxygenation, 220, 221, 222
 oxygen-carrying solutions, 47
 oxygen–hemoglobin
 dissociation curve, 90, 90
- pancreatitis, 179
 Particle Gel Immunoassay, 54
 pediatric patients, 229
 anesthesia, 230
 complications following
 CPB, 236
 drug administration on
 bypass, 234
 extracorporeal membrane
 oxygenation, 236–237
 monitoring, 230–231, 234–235
 anticoagulation, 234
 blood gases, 235
 glucose control, 235
 preoperative issues, 229
 preparation for CPB, 231–234
 cell salvage, 231
 circuit set-up, 231–234
 separation from bypass, 235–236
 temperature management, 235
 perioperative myocardial
 infarction, 101
 pH. *See* acid–base metabolism
 pharmacologic
 preconditioning, 110
 phosphate, 94
 plasmin, 172
 platelet abnormalities, 60–61, 63
 platelet factor 4 (PF4), 57
 platelet function tests, 59–60, 61
 agonist-induced point-of-care tests, 60
 thromboelastography (TEG), 59–60
- potassium, 93, 117
 pre-bypass checklist, 28, 29
 pressure alarms, 40
 priming, 37–39, 42
 autologous blood priming, 43, 88–89
 hemodilution, 42–43
 mini-bypass system, 28, 42
 prime volume, 42, 231–232
 solutions, 44–47
 additives, 46–47
 blood, 44
 colloids, 45–46
 crystalloids, 44–45
 experimental oxygen-carrying solutions, 47
 metabolic effects, 87–89
 pediatric patients, 231–233
 procaine, 106
 protamine, 57, 124–125
 dosing, 62
 prothrombin complex
 concentrate (PCC), 63
 pulmonary artery pressure, 78
 pulmonary complications, 180
 pulmonary embolism, 244–245
 pumps, 7–9
 centrifugal pumps, 9, 10, 220
 extracorporeal membrane
 oxygenation, 219–220
 roller pumps, 7–9, 8
 PVC, 3
- quality of life, 183
- recombinant factor VIIa (rFVIIa), 64
 remote ischemic preconditioning (RIPC), 109
 renal injury. *See* acute kidney injury (AKI)
 renal replacement therapy, 210–211
 pediatric patients, 234
 reservoirs, 9–11, 10
 respiratory acidosis, 92
 respiratory alkalosis, 92
 retrograde cerebral perfusion (RCP), 91, 160
 versus antegrade cerebral perfusion, 161
 re-warming, 84–85, 116–117
 deep hypothermic
 circulatory arrest, 157
 from severe hypothermia, 239–240
- right atrial cannulation, 71
 right ventricular assist device (RVAD), 136
 right ventricular failure, 147, 147
 roller pumps, 7–9, 8
 Rotational
 Thromboelastometry (ROTEM), 59, 60
- safety issues, 28–30, 31
 during CPB, 31
 electronic safety devices, 40–41
 extracorporeal membrane
 oxygenation, 222
 key safety factors, 32
 pre-bypass concerns, 30
 separation from CPB, 31
 serotonin-release assay (SRA), 54
 silicone rubber, 3
 siphon effect, 70
 sodium bicarbonate, 47, 121
 sodium valproate, 162
 somatosensory evoked potentials (SSEPs), 164
 Sonoclot test, 59, 60
 spinal cord protection, 162
 starches, 46
 hydroxyethyl starch (HES)
 priming solution, 46
- statins, 112, 181–182, 208
 stroke. *See also* cerebral ischemia
 following deep hypothermic
 circulatory arrest, 165
 perioperative, 188, 190–194
 aortic clamping
 relationships, 192–193
 epiaortic scanning
 application, 191
 off-pump coronary artery
 bypass graft and, 191–192, 192
 timing of, 193, 193–194, 195
 prevalence in the general
 population, 194–197, 196
 secondary events, 197
 suckers, 15–16

Cambridge University Press

978-1-107-42825-6 - Cardiopulmonary Bypass: Second Edition

Edited by Sunit Ghosh, Florian Falter and Albert C. Perrino

Index

[More information](#)

260

Index

- systemic inflammatory response syndrome (SIRS), 61, 169, 169–173
- acute kidney injury etiology, 207
- cellular injury, 172–173
- gastrointestinal effects, 178
- initiation, 169–172
- therapeutic strategies, 181–182
- temperature alarms, 40
- temperature management, 79, **80**, *See also* hypothermia
- flow rate relationship, 90
- pediatric patients, 235
- thiopental, 162
- thoracic aortic aneurysms, 249–250
- reducing spinal cord ischemia during surgery, 250
- thoracic aortic dissection, 248–249
- Thoratec CentriMag, **140–142**, 141, 142
- cannulation, 143
- thrombocytopenia, 60–61, 63, *See also* heparin-induced thrombocytopenia (HIT)
- thromboelastography (TEG), 59, 59–60
- pediatric patients, 235
- total arterial grafting, 192–193
- tranexamic acid (TA), 62, 63, 182
- pediatric patients, 230
- transcranial Doppler (TCD), 164
- transesophageal echocardiography (TEE), 80
- pediatric patients, 231
- role in weaning from CPB, 124, **125**
- transfusion algorithms, 64
- transient ischemic attacks (TIAs), 196
- trauma care, 240–241
- tris-hydroxymethyl aminomethane (THAM), 106
- tubing, 2–4
- sizes, 3
- tumor resection, 245
- ultrafilters, 17
- unfractionated heparin. *See* heparin
- uninterruptible power supply (UPS), 25
- urine volume, 79
- vasoactive drugs, 118
- vasopressin, 128
- veno-arterial extracorporeal membrane oxygenation (VA ECMO), 130, 218–219
- venous cannulae, 6–7, 7
- venous cannulation, 70–72
- connection to the patient, 71–72
- pediatric patients, 233
- peripheral, 72
- complications, 72
- veno-venous extracorporeal membrane oxygenation (VV ECMO), 217–218
- venting the heart, 74–75
- left heart, 74
- right heart, 74
- venting methods, 75
- ventricular assist devices (VADs), 130, 136–150
- complications, **149**
- contraindications, **140**
- decision-making process, 137–139
- profiles, **137**, 137–139
- left ventricular assist device (LVAD), 136, 148–149
- patient management, 146–150
- long-term care, 150
- perioperative management, 147, **148**
- postoperative management, 149–150
- preoperative management, 146
- weaning from CPB with VAD support, 148–149
- principles of, 136
- right ventricular assist device (RVAD), 136
- types of, 139–145, **140**
- vents, 15–16
- weaning from CPB, 80–81, 116
- checklist before weaning, **80**
- events immediately prior to, 120–122
- alarm settings adjustment, 120
- blood gases and electrolytes analysis, 121
- de-airing the heart, 121
- epicardial pacing, 121–122
- mechanical ventilation, 120
- failure to achieve, 125–130
- mechanical support, 129–130
- reinstitution of CPB, 125–126
- vasopressor and inotropic support, 126–129
- pediatric patients, 235–236
- predicting difficulty, 119–120
- preparation for, 116–119, **117**
- anesthesia, 119
- cardiac function, 119
- coagulation, 118
- electrolytes and acid/base balance, 117–118
- fluid replacement, 118
- hemoglobin concentration, 118
- re-warming, 116–117
- vasoactive drugs, 118
- separation mechanics, 122–124
- afterload assessment, 123–124
- contractility assessment and inotropic support, 123
- preload assessment and adjustment, 123
- transesophageal echocardiography role, 124, **125**
- VAD support, 148–149
- whole blood impedance aggregometry (WBIA), 54